Guest guest Posted December 27, 2010 Report Posted December 27, 2010 Immune activation by casein dietary antigens in bipolar disorder. Severance EG, Dupont D, Dickerson FB, Stallings CR, Origoni AE, Krivogorsky B, Yang S, Haasnoot W, Yolken RH. Bipolar Disord. 2010 Dec;12(8):834-42. doi: 10.1111/j.1399-5618.2010.00879.x. http://www.ncbi.nlm.nih.gov/pubmed/21176030 Abstract Severance EG, Dupont D, Dickerson FB, Stallings CR, Origoni AE, Krivogorsky B, Yang S, Haasnoot W, Yolken RH. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord 2010: 12: 834-842. © 2010 The Authors. Journal compilation © 2010 Wiley & Sons A/S. Objectives:  Inflammation and other immune processes are increasingly linked to psychiatric diseases. Antigenic triggers specific to bipolar disorder are not yet defined. We tested whether antibodies to bovine milk caseins were associated with bipolar disorder, and whether patients recognized different epitopes of the casein protein than control individuals. Methods:  Anti-bovine casein immunoglobulin G (IgG) levels were measured with solid-phase immunoassays in 75 individuals with bipolar disorder and 65 controls. Epitope recognition was evaluated in immunoassays by cross neutralization with anti-bovine casein polyclonal antibodies of defined reactivity. Group-specific reactivity and associations with symptom severity scores were detected with age-, gender-, and race-controlled regression models. Results:  Individuals with bipolar disorder had significantly elevated anti-casein IgG (t-test, p ≤ 0.001) compared to controls. Casein IgG seropositivity conferred odds ratios of 3.97 for bipolar disorder [n = 75, 95% confidence interval (CI): 1.31-12.08, p ≤ 0.015], 5.26 for the bipolar I subtype (n = 56, 95% CI: 1.66-16.64, p ≤ 0.005), and 3.98 for bipolar disorder with psychosis (n = 54, 95% CI: 1.32-12.00, p ≤ 0.014). Lithium and/or antipsychotic medication did not significantly affect anti-casein IgG levels. Casein IgG measures correlated with severity of manic (R(2)  = 0.15, 95% CI: 0.05-0.24, p ≤ 0.02) but not depressive symptoms. Unlike controls, sera from individuals with bipolar disorder did not inhibit binding of casein-reactive animal sera (t-test/χ(2) , p ≤ 0.0001). Conclusions:  Anti-casein IgG associations with bipolar I diagnoses, psychotic symptom history, and mania severity scores suggest that casein-related immune activation may relate to the psychosis and mania components of this mood disorder. Case-control differences in epitope recognition implicate disease-related alterations in how the casein molecule is digested and/or how resulting casein-derived structures are rendered immunogenic. © 2010 Wiley and Sons A/S. PMID: 21176030 [PubMed - in process] Quote
Guest guest Posted December 27, 2010 Report Posted December 27, 2010 Thus we might ask whether casein hypersensitivity (2) while pregnant or during infancy alters bipolar-related dysmethylation (1). 1. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. <http://www.ncbi.nlm.nih.gov/pubmed/18319075> Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, Wang SC, Petronis A. Am J Hum Genet. 2008 Mar;82(3):696-711. Epigenetic misregulation is consistent with various non-Mendelian features of schizophrenia and bipolar disorder. To date, however, few studies have investigated the role of DNA methylation in major psychosis, and none have taken a genome-wide epigenomic approach. In this study we used */CpG-island microarrays to identify DNA-methylation changes in the frontal cortex and germline/* associated with schizophrenia and bipolar disorder. In the frontal cortex we find evidence for psychosis-associated DNA-methylation differences in numerous loci, including several involved in glutamatergic and GABAergic neurotransmission, brain development, and other processes functionally linked to disease etiology. DNA-methylation changes in a significant proportion of these loci correspond to reported changes of steady-state mRNA level associated with psychosis. Gene-ontology analysis highlighted epigenetic disruption to loci involved in mitochondrial function, brain development, and stress response. */Methylome network analysis uncovered decreased epigenetic modularity in both the brain and the germline of affected individuals, suggesting that systemic epigenetic dysfunction may be associated with major psychosis/*. We also report evidence for a strong correlation between DNA methylation in the MEK1 gene promoter region and lifetime antipsychotic use in schizophrenia patients. Finally, we observe that frontal-cortex DNA methylation in the BDNF gene is correlated with genotype at a nearby nonsynonymous SNP that has been previously associated with major psychosis. Our data are consistent with the epigenetic theory of major psychosis and suggest that DNA-methylation changes are important to the etiology of schizophrenia and bipolar disorder. 2. *Immune activation by casein dietary antigens in bipolar disorder* Severance EG, Dupont D, Dickerson FB, Stallings CR, Origoni AE, Krivogorsky B, Yang S, Haasnoot W, Yolken RH. Bipolar Disord. 2010 Dec;12(8):834-42. doi: 10.1111/j.1399-5618.2010.00879.x. http://www.ncbi.nlm.nih.gov/pubmed/21176030 Abstract Severance EG, Dupont D, Dickerson FB, Stallings CR, Origoni AE, Krivogorsky B, Yang S, Haasnoot W, Yolken RH. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord 2010: 12: 834-842. © 2010 The Authors. Journal compilation © 2010 Wiley & Sons A/S. Objectives:  Inflammation and other immune processes are increasingly linked to psychiatric diseases. Antigenic triggers specific to bipolar disorder are not yet defined. We tested whether antibodies to bovine milk caseins were associated with bipolar disorder, and whether patients recognized different epitopes of the casein protein than control individuals. Methods:  Anti-bovine casein immunoglobulin G (IgG) levels were measured with solid-phase immunoassays in 75 individuals with bipolar disorder and 65 controls. Epitope recognition was evaluated in immunoassays by cross neutralization with anti-bovine casein polyclonal antibodies of defined reactivity. Group-specific reactivity and associations with symptom severity scores were detected with age-, gender-, and race-controlled regression models. Results:  Individuals with bipolar disorder had significantly elevated anti-casein IgG (t-test, p ≤ 0.001) compared to controls. Casein IgG seropositivity conferred odds ratios of 3.97 for bipolar disorder [n = 75, 95% confidence interval (CI): 1.31-12.08, p ≤ 0.015], 5.26 for the bipolar I subtype (n = 56, 95% CI: 1.66-16.64, p ≤ 0.005), and 3.98 for bipolar disorder with psychosis (n = 54, 95% CI: 1.32-12.00, p ≤ 0.014). Lithium and/or antipsychotic medication did not significantly affect anti-casein IgG levels. Casein IgG measures correlated with severity of manic (R(2)  = 0.15, 95% CI: 0.05-0.24, p ≤ 0.02) but not depressive symptoms. Unlike controls, sera from individuals with bipolar disorder did not inhibit binding of casein-reactive animal sera (t-test/χ(2) , p ≤ 0.0001). Conclusions:  Anti-casein IgG associations with bipolar I diagnoses, psychotic symptom history, and mania severity scores suggest that casein-related immune activation may relate to the psychosis and mania components of this mood disorder. Case-control differences in epitope recognition implicate disease-related alterations in how the casein molecule is digested and/or how resulting casein-derived structures are rendered immunogenic. © 2010 Wiley and Sons A/S. PMID: 21176030 [PubMed - in process] Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.